Clinical Trial Update: Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab in combination with BCG after ablation for high-risk upper tract urothelial carcinoma without nephroureterectomy; not yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Upper Tract Urothelial Carcinoma

Drugs mentioned

• BCG (Bacillus Calmette-Guérin)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Shaheen Alanee | Conditions: High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma, Endoscopic Surgical Procedure | Phase 2 | Status: NOT_YET_RECRUITING